Yongqing Luo, CEO of Genting New Era (01952.HK), stated that the Asia Phase III clinical study of the highly selective corticosteroid-1-phosphate receptor modulator "velsipidy" (iquimod) for the treatment of moderate to severe active ulcerative colitis achieved positive top-line results with clinical and statistical significance in the maintenance period data. They will strive to submit a new drug application for iquimod for marketing approval in China and other authorized regions as soon as possible.

Iquimod has been approved for marketing in the United States and the European Union in October last year and February this year, and has become the first and only new generation oral treatment for ulcerative colitis approved for patients aged 16 and above in the European Union. In addition, the product has also been approved for marketing by the Macau Drug Supervision and Administration Bureau in April of this year.